Cargando…

Interruption of vascular endothelial growth factor receptor 2 signaling induces a proliferative pulmonary vasculopathy and pulmonary hypertension

Pulmonary arterial hypertension is a severe and progressive disease characterized by a pulmonary vascular remodeling process with expansion of collateral endothelial cells and total vessel occlusion. Endothelial cells are believed to be at the forefront of the disease process. Vascular endothelial g...

Descripción completa

Detalles Bibliográficos
Autores principales: Winter, Max-Paul, Sharma, Smriti, Altmann, Johanna, Seidl, Veronika, Panzenböck, Adelheid, Alimohammadi, Arman, Zelniker, Thomas, Redwan, Bassam, Nagel, Felix, Santer, David, Stieglbauer, Alexander, Podesser, Bruno, Sibilia, Maria, Helbich, Thomas, Prager, Gerald, Ilhan-Mutlu, Aysegül, Preusser, Matthias, Lang, Irene M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7471204/
https://www.ncbi.nlm.nih.gov/pubmed/32880713
http://dx.doi.org/10.1007/s00395-020-0811-5
_version_ 1783578735458385920
author Winter, Max-Paul
Sharma, Smriti
Altmann, Johanna
Seidl, Veronika
Panzenböck, Adelheid
Alimohammadi, Arman
Zelniker, Thomas
Redwan, Bassam
Nagel, Felix
Santer, David
Stieglbauer, Alexander
Podesser, Bruno
Sibilia, Maria
Helbich, Thomas
Prager, Gerald
Ilhan-Mutlu, Aysegül
Preusser, Matthias
Lang, Irene M.
author_facet Winter, Max-Paul
Sharma, Smriti
Altmann, Johanna
Seidl, Veronika
Panzenböck, Adelheid
Alimohammadi, Arman
Zelniker, Thomas
Redwan, Bassam
Nagel, Felix
Santer, David
Stieglbauer, Alexander
Podesser, Bruno
Sibilia, Maria
Helbich, Thomas
Prager, Gerald
Ilhan-Mutlu, Aysegül
Preusser, Matthias
Lang, Irene M.
author_sort Winter, Max-Paul
collection PubMed
description Pulmonary arterial hypertension is a severe and progressive disease characterized by a pulmonary vascular remodeling process with expansion of collateral endothelial cells and total vessel occlusion. Endothelial cells are believed to be at the forefront of the disease process. Vascular endothelial growth factor (VEGF) and its tyrosine kinase receptor, VEGF receptor-2 (VEGFR-2), play a central role in angiogenesis, endothelial cell protection, but also in the destabilization of endothelial barrier function. Therefore, we investigated the consequences of altered VEGF signaling in an experimental model, and looked for translational correlates of this observation in patients. We performed an endothelial cell-specific conditional deletion of the kinase insert domain protein receptor (kdr) gene, coding for VEGFR-2, in C57/BL6 mice (Kdr(∆end)) and held them in an environmental chamber with 10% FiO(2) or under normoxia for 6 weeks. Kdr knockout led to a mild PH phenotype under normoxia that worsened under hypoxia. Kdr(∆end) mice exhibited a significant increase in pulmonary arterial wall thickness, muscularization, and VEGFR-3(+) endothelial cells obliterating the pulmonary artery vessel lumen. We observed the same proliferative vasculopathy in our rodent model as seen in patients receiving anti-angiogenic therapy. Serum VEGF-a levels were elevated both in the experimental model and in humans receiving bevacizumab. Interrupted VEGF signaling leads to a pulmonary proliferative arteriopathy in rodents after direct ablative gene manipulation of Kdr. Histologically, similar vascular lesions can be observed in patients receiving anti-VEGF treatment. Our findings illustrate the importance of VEGF signaling for maintenance of pulmonary vascular patency. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00395-020-0811-5) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-7471204
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-74712042020-09-16 Interruption of vascular endothelial growth factor receptor 2 signaling induces a proliferative pulmonary vasculopathy and pulmonary hypertension Winter, Max-Paul Sharma, Smriti Altmann, Johanna Seidl, Veronika Panzenböck, Adelheid Alimohammadi, Arman Zelniker, Thomas Redwan, Bassam Nagel, Felix Santer, David Stieglbauer, Alexander Podesser, Bruno Sibilia, Maria Helbich, Thomas Prager, Gerald Ilhan-Mutlu, Aysegül Preusser, Matthias Lang, Irene M. Basic Res Cardiol Original Contribution Pulmonary arterial hypertension is a severe and progressive disease characterized by a pulmonary vascular remodeling process with expansion of collateral endothelial cells and total vessel occlusion. Endothelial cells are believed to be at the forefront of the disease process. Vascular endothelial growth factor (VEGF) and its tyrosine kinase receptor, VEGF receptor-2 (VEGFR-2), play a central role in angiogenesis, endothelial cell protection, but also in the destabilization of endothelial barrier function. Therefore, we investigated the consequences of altered VEGF signaling in an experimental model, and looked for translational correlates of this observation in patients. We performed an endothelial cell-specific conditional deletion of the kinase insert domain protein receptor (kdr) gene, coding for VEGFR-2, in C57/BL6 mice (Kdr(∆end)) and held them in an environmental chamber with 10% FiO(2) or under normoxia for 6 weeks. Kdr knockout led to a mild PH phenotype under normoxia that worsened under hypoxia. Kdr(∆end) mice exhibited a significant increase in pulmonary arterial wall thickness, muscularization, and VEGFR-3(+) endothelial cells obliterating the pulmonary artery vessel lumen. We observed the same proliferative vasculopathy in our rodent model as seen in patients receiving anti-angiogenic therapy. Serum VEGF-a levels were elevated both in the experimental model and in humans receiving bevacizumab. Interrupted VEGF signaling leads to a pulmonary proliferative arteriopathy in rodents after direct ablative gene manipulation of Kdr. Histologically, similar vascular lesions can be observed in patients receiving anti-VEGF treatment. Our findings illustrate the importance of VEGF signaling for maintenance of pulmonary vascular patency. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00395-020-0811-5) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2020-09-03 2020 /pmc/articles/PMC7471204/ /pubmed/32880713 http://dx.doi.org/10.1007/s00395-020-0811-5 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Original Contribution
Winter, Max-Paul
Sharma, Smriti
Altmann, Johanna
Seidl, Veronika
Panzenböck, Adelheid
Alimohammadi, Arman
Zelniker, Thomas
Redwan, Bassam
Nagel, Felix
Santer, David
Stieglbauer, Alexander
Podesser, Bruno
Sibilia, Maria
Helbich, Thomas
Prager, Gerald
Ilhan-Mutlu, Aysegül
Preusser, Matthias
Lang, Irene M.
Interruption of vascular endothelial growth factor receptor 2 signaling induces a proliferative pulmonary vasculopathy and pulmonary hypertension
title Interruption of vascular endothelial growth factor receptor 2 signaling induces a proliferative pulmonary vasculopathy and pulmonary hypertension
title_full Interruption of vascular endothelial growth factor receptor 2 signaling induces a proliferative pulmonary vasculopathy and pulmonary hypertension
title_fullStr Interruption of vascular endothelial growth factor receptor 2 signaling induces a proliferative pulmonary vasculopathy and pulmonary hypertension
title_full_unstemmed Interruption of vascular endothelial growth factor receptor 2 signaling induces a proliferative pulmonary vasculopathy and pulmonary hypertension
title_short Interruption of vascular endothelial growth factor receptor 2 signaling induces a proliferative pulmonary vasculopathy and pulmonary hypertension
title_sort interruption of vascular endothelial growth factor receptor 2 signaling induces a proliferative pulmonary vasculopathy and pulmonary hypertension
topic Original Contribution
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7471204/
https://www.ncbi.nlm.nih.gov/pubmed/32880713
http://dx.doi.org/10.1007/s00395-020-0811-5
work_keys_str_mv AT wintermaxpaul interruptionofvascularendothelialgrowthfactorreceptor2signalinginducesaproliferativepulmonaryvasculopathyandpulmonaryhypertension
AT sharmasmriti interruptionofvascularendothelialgrowthfactorreceptor2signalinginducesaproliferativepulmonaryvasculopathyandpulmonaryhypertension
AT altmannjohanna interruptionofvascularendothelialgrowthfactorreceptor2signalinginducesaproliferativepulmonaryvasculopathyandpulmonaryhypertension
AT seidlveronika interruptionofvascularendothelialgrowthfactorreceptor2signalinginducesaproliferativepulmonaryvasculopathyandpulmonaryhypertension
AT panzenbockadelheid interruptionofvascularendothelialgrowthfactorreceptor2signalinginducesaproliferativepulmonaryvasculopathyandpulmonaryhypertension
AT alimohammadiarman interruptionofvascularendothelialgrowthfactorreceptor2signalinginducesaproliferativepulmonaryvasculopathyandpulmonaryhypertension
AT zelnikerthomas interruptionofvascularendothelialgrowthfactorreceptor2signalinginducesaproliferativepulmonaryvasculopathyandpulmonaryhypertension
AT redwanbassam interruptionofvascularendothelialgrowthfactorreceptor2signalinginducesaproliferativepulmonaryvasculopathyandpulmonaryhypertension
AT nagelfelix interruptionofvascularendothelialgrowthfactorreceptor2signalinginducesaproliferativepulmonaryvasculopathyandpulmonaryhypertension
AT santerdavid interruptionofvascularendothelialgrowthfactorreceptor2signalinginducesaproliferativepulmonaryvasculopathyandpulmonaryhypertension
AT stieglbaueralexander interruptionofvascularendothelialgrowthfactorreceptor2signalinginducesaproliferativepulmonaryvasculopathyandpulmonaryhypertension
AT podesserbruno interruptionofvascularendothelialgrowthfactorreceptor2signalinginducesaproliferativepulmonaryvasculopathyandpulmonaryhypertension
AT sibiliamaria interruptionofvascularendothelialgrowthfactorreceptor2signalinginducesaproliferativepulmonaryvasculopathyandpulmonaryhypertension
AT helbichthomas interruptionofvascularendothelialgrowthfactorreceptor2signalinginducesaproliferativepulmonaryvasculopathyandpulmonaryhypertension
AT pragergerald interruptionofvascularendothelialgrowthfactorreceptor2signalinginducesaproliferativepulmonaryvasculopathyandpulmonaryhypertension
AT ilhanmutluaysegul interruptionofvascularendothelialgrowthfactorreceptor2signalinginducesaproliferativepulmonaryvasculopathyandpulmonaryhypertension
AT preussermatthias interruptionofvascularendothelialgrowthfactorreceptor2signalinginducesaproliferativepulmonaryvasculopathyandpulmonaryhypertension
AT langirenem interruptionofvascularendothelialgrowthfactorreceptor2signalinginducesaproliferativepulmonaryvasculopathyandpulmonaryhypertension